BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Janssen Posts Positive HDFN Data Amid Reports of Global Overhaul

  Janssen reported positive topline data from a Phase II proof of concept study assessing nipocalimab in severe hemolytic disease of the fetus and newborn.

  February 6, 2023

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Drug Development

  GEN2 NASH Therapies Near the Finish Line

  Industry leaders say the second generation of interventions for nonalcoholic steatohepatitis is likely to succeed where first-generation approaches stumbled.

  February 6, 2023

   · 

  4 min read

   · 

  Gail Dutton
• 

  Confidentiality Agreements and Severance Pay: a Comprehensive Guide

  If you’ve recently lost your job, BioSpace has provided a guide to confidentiality agreements and severance packages so you can feel confident making your next career move.

  February 6, 2023

   · 

  3 min read

   · 

  Christie Adams
• 

  Drug Development

  4D’s Fabry Gene Therapy on Ice After FDA-Mandated Pause

  The FDA placed 4D Molecular Therapeutics’ gene therapy program, 4D-310, on clinical hold, the company announced Thursday.

  February 6, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Biogen’s $1.5B Bet for Depressive Disorders Heads to FDA (Updated)

  Biogen and its partner, Sage Therapeutics, announced the FDA has accepted the New Drug Application for zuranolone and granted it priority review in two mental health indications.

  February 6, 2023

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Astellas Taps New CEO in Nod to Accelerated Growth

  Astellas named a new president and CEO and announced additional changes to its leadership structure in an effort to accelerate growth and chart its long-term business trajectory.

  February 6, 2023

   · 

  2 min read

   · 

  Tristan Manalac
• Genetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian Cancer

  Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is delighted to provide further update.

  February 6, 2023

   · 

  8 min read
• Drug Development

  Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN).

  February 6, 2023

   · 

  8 min read
• Business

  Ultima Genomics and Integrated DNA Technologies to Enable Application Portfolio on Ultima Sequencing Platforms

  Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, today announced a strategic collaboration with global genomics solutions provider Integrated DNA Technologies (IDT) to enable key next generation sequencing (NGS) applications on Ultima platforms.

  February 6, 2023

   · 

  4 min read
• Business

  Aethlon Medical to Release Third Quarter Financial Results and Host Conference Call on February 13, 2023

  Aethlon Medical, Inc. (NASDAQ: AEMD), a company developing medical therapeutics to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its third quarter ended December 31, 2022, at 4:15 p.m. EST on Monday, February 6, 2023.

  February 6, 2023

   · 

  2 min read